Welcome to our dedicated page for RenovoRx news (Ticker: $RNXT), a resource for investors and traders seeking the latest updates and insights on RenovoRx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RenovoRx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RenovoRx's position in the market.
RenovoRx, a clinical-stage biopharmaceutical company (Nasdaq: RNXT), will take part in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024. CEO Shaun Bagai will discuss the company's recent milestones, including raising $17.2 million through private placements. This funding will support RenovoRx's Phase III TIGeR-PaC clinical trial for its lead product, RenovoGem, aimed at treating locally advanced pancreatic cancer. The TIGeR-PaC's second interim analysis is anticipated by late 2024. The event will be moderated by Scott Henry, Managing Director at A.G.P.
RenovoRx, Inc. (RNXT) CEO Shaun R. Bagai will present at the Aegis Capital Virtual Conference on May 9, 2024. The company recently completed private placements raising $17.2 million. This funding will support the Phase III TIGeR-PaC clinical trial for RenovoGem™ in locally advanced pancreatic cancer. The second interim analysis is expected in late 2024.